AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data
AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. This functionality provides higher-quality data and less delays, making it the most efficient method to collect and transfer Holter data, spectral-domain OCT and newer modalities not yet conforming to the DICOM standard.
Now, meta-data can be assigned to non-DICOM modalities and used for configuring, on a per-study basis, structured directories with explicit hierarchies based on the acquired meta-data. This is especially important for:
“In combination with our ability to tag and deliver this data not just to DICOM repositories but also to local file systems, we’re providing cardiovascular trials, as well as projects requiring specialized non-DICOM modalities, with a way to ensure higher quality and less delays than other methods,” said Abraham Gutman, President & CEO of AG Mednet.
For more information about AG Mednet, please visit www.agmednet.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.